Calling Bioatla LLC's Conditionally Active Biologics (CAB) platform "the key piece for getting [an antibody-drug conjugate (ADC)] where it needs to go," CEO Jay Short told BioWorld Today the new deal with Pfizer Inc. represents "the marrying of two world-class technologies."